Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Prof Domingo Pascual Figal (Hospital Clinico Universitario Virgen de la Arrixaca, SP) discusses the DAPA MODA study (NCT04707352).

The study aimed to assess the effects of dapagliflozin on cardiac remodeling parameters, particularly LA geometry and function, and biomarkers reflecting pathophysiological pathways. Findings from HFA 2023 revealed that dapagliflozin administration in stable out-setting chronic HF patients with optimised therapy resulted in global reverse remodelling of cardiac structure, including reduced LA volumes, improved LV geometry and decreased NT-proBNP concentrations at 180 days.

Interview Questions:
1. What is known about SGLT2is' mechanism and study importance?
2. What is the study design, methodology, and outcomes?
3. What are the key findings?
4. What are the take-home messages?
5. How do the effects of dapagliflozin compare with other available treatments?

Recored on-site at HFA 2023, Prague.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter:

Чтобы скачать видео "HFA 23: DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF" передвинте ползунок вправо